Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01247922 · ClinicalTrials.gov registry record · Phase 2
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
A Phase 2 study, sponsored by OSI Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01247922 is a Phase 2 study that was terminated before completion, run by OSI Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT01247922, a Phase 2 study, was terminated before completion, sponsored by OSI Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide were allowed to participate in this study to assess the safety profile of single-agent erlotinib in participants with recurrent or refractory pediatric ependymoma.
Interventions
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-05-23 |
| Est. Completion | 2012-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01247922
The ClinicalTrials.gov registry entry for NCT01247922 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erlotinib is the first listed.
NCT01247922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01247922 about?
NCT01247922 is a clinical study titled "Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205". Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide were allowed to participate in this study to assess the safety profile of single-agent erlotinib in parti...
What is the current status of trial NCT01247922?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2011-05-23. Estimated completion is 2012-09-13.
What interventions are being tested in trial NCT01247922?
The interventions under investigation include: Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01247922?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.